Sequana Medical NV (EBR:SEQUA)

Market Cap	43.56M -18.7%
Revenue (ttm)	n/a -85.2%
Net Income	-51.85M
EPS	-1.11
Shares Out	71.29M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	653,150
Open	0.6690
Previous Close	0.6110
Day's Range	0.5600 - 0.6690
52-Week Range	0.4600 - 1.6180
Beta	-0.29
Analysts	n/a
Price Target	n/a
Earnings Date	Jun 25, 2026

About Sequana Medical NV

Sequana Medical NV develops and commercializes treatments for patients with diuretic-resistant fluid overload in liver disease, cancer, and heart failure in Belgium, Germany, France, and internationally. The company offers alfapump system, an implantable pump system for the treatment of refractory liver ascites and malignant ascites; and Direct Sodium Removal (DSR) for the treatment of fluid overload spread across the body. Sequana Medical NV was founded in 2006 and is headquartered in Gent, Belgium.

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2006
• Employees: 48
• Stock Exchange: Euronext Brussels
• Ticker Symbol: SEQUA

Financial Performance

In 2024, Sequana Medical NV's revenue was 105,500, a decrease of -85.19% compared to the previous year's 712,173. Losses were -44.65 million, 37.1% more than in 2023.